Danish pharmaceutical company Novo Nordisk rose by 5.3 percent in Copenhagen, reaching its highest level since September during the trading day.

The company is among the top gainers in Europe ahead of the release of U.S. prescription data eagerly awaited by analysts, according to Reuters. Novo Nordisk's weight-loss pill became available to American patients on January 5. According to analysts at Sydbank, the stock's movement is being driven by strong early prescription data for the Wegovy pill in the United States.

Novo Nordisk has also received approval in the United Kingdom for a maximum dose of up to 7.2 milligrams per week of Wegovy. The approval applies exclusively to obesity treatment and allows for a higher permitted dose than previously authorized.